Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Technologies Introduces Next-Generation Sequencing Cancer Research Panels

Published: Tuesday, September 02, 2014
Last Updated: Tuesday, September 02, 2014
Bookmark and Share
High-performance ClearSeq AML to be followed by series of focused, comprehensive gene panels for cancer research.

Agilent Technologies Inc. today introduced ClearSeq AML, the first product in the ClearSeq line of next-generation cancer research panels, which targets 48 selected exons in 20 of the most commonly mutated genes found in acute myeloid leukemia.

Designed in collaboration with Dr. Robert Ohgami and Dr. Daniel Arber at the Stanford Department of Pathology, Stanford University, ClearSeq AML provides comprehensive coverage of mutations and enables swift progression of sample processing to analysis in less than 48 hours. The AML gene panel will be followed by the release of additional ClearSeq panels for cancer research throughout the coming months.

"We are pleased to introduce the ClearSeq family of products, a comprehensive set of targeted NGS gene panels for cancer research," said Jacob Thaysen, vice president and general manager of Agilent's Diagnostics and Genomics Group. "ClearSeq NGS panels are expert-identified products that will provide customers with a complete end-to-end anatomical-to-molecular genomics portfolio that includes solutions ranging from IHC for cancer diagnosis to NGS for cancer research."

Acute myeloid leukemia (AML) is the most common myeloid neoplasm affecting adults, and the role of chromosomal structural variations in its molecular pathogenesis is well documented. In recent years, next-generation sequencing has led to a revolution in the study of hematological malignancies and shown that insertions, deletions (indels) and mutations play an essential part in the pathogenesis of AML. Genetic information coupled with standard anatomical findings has provided a deeper characterization and classification of AML.

ClearSeq AML provides 99.9 percent design coverage of targeted coding exons. Agilent's high-performance cancer panels enable the study of more complex genomic alterations in cancer, and deliver quick and accurate identification of relevant information. ClearSeq panels are based on SureSelect and HaloPlex technology, offering superior sensitivity and accuracy compared with other hybridization or PCR-based methods, thus minimizing the risk of false-positive results. ClearSeq panels can be easily incorporated into routine laboratory workflows. Sequence data analysis and mutation reporting can be completed in three simple steps using Agilent's SureCall software.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Technologies Introduces First Commercial Software
Company has introduced new software to help cancer researchers in metabolic flux analysis.
Tuesday, April 19, 2016
Agilent, ASI Announce Agreement
Company has announced co-marketing agreement with ASI for fluorescence in situ hybridization.
Friday, April 08, 2016
Agilent Technologies and Eurofins Genomics Collaborate
Company has announced collaboration with Eurofins Genomics to expand SureVector cloning system.
Tuesday, March 22, 2016
Agilent Technologies to Sponsor USCAP 2016
Company has announced that it will be a Silver sponsor of USCAP 2016, the annual gathering of the United States and Canadian Academy of Pathology.
Thursday, March 10, 2016
Agilent Names CNAG as Certified Provider of Target-Enrichment Services
Centro Nacional de Análisis Genómico (CNAG) in Barcelona is one of Europe’s leading genome analysis centers.
Monday, February 23, 2015
Agilent to Close NMR Business
The announcement is part of Agilent's strategy to address the business shortfalls of its Research Products Division.
Wednesday, October 15, 2014
Agilent Technologies, University of Toronto to Collaborate on Metabolomics MRM Library-Software Solution
Scientists will be provided with a robust LC/MS solution to accelerate cell biology, disease research.
Tuesday, September 30, 2014
Agilent, Seoul National University to Collaborate on New Research Center
The facility will support new drug development center in the university's college of pharmacy.
Tuesday, May 13, 2014
Agilent Introduces Enhanced Electronic Laboratory Notebook
OpenLAB ELN integrates scientific results from multiple analytical software applications, quickly and easily.
Tuesday, November 19, 2013
Agilent and Daegu Gyeongbuk Institute of Science and Technology Collaborate
Neurometabolomics Center will use Agilent's bio-analytical instruments in research of biomarkers for early detection and diagnosis of brain diseases.
Friday, November 01, 2013
Agilent Combines Its Life Sciences and Diagnostics Businesses
Decision follows Agilent's announcement that it plans to separate the company into two independent publicly traded companies.
Thursday, September 19, 2013
Agilent to Acquire Assets from ABC Instrumentación Analítica
The companies have signed a definitive agreement for Agilent to acquire assets from the privately held Mexican distributor.
Thursday, September 05, 2013
Agilent Reports Third-Quarter Results
Revenues were $1.65 billion for the third fiscal quarter ended July 31, 2013, down 4 percent over one year ago.
Thursday, August 15, 2013
Agilent Technologies Triple Quadrupole ICP-MS Selected for R&D 100 Award
These prestigious awards recognize the 100 most technologically significant products introduced into the marketplace over the past year.
Monday, July 15, 2013
Agilent to Host Forensics Webinar
The webinar, which will be held on June 20, will focus on LC/MS/MS methods for cannabinoid and benzodiazepine quantitation in whole blood samples.
Wednesday, June 05, 2013
Scientific News
Computational Model Finds New Protein-Protein Interactions
Researchers at University of Pittsburgh have discovered 500 new protein-protein interactions (PPIs) associated with genes linked to schizophrenia.
Experimental Drug Cancels Effect from Key Intellectual Disability Gene
A University of Wisconsin—Madison researcher who studies the most common genetic intellectual disability has used an experimental drug to reverse — in mice — damage from the mutation that causes the syndrome.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Bioreactors Ready for the Big Time
Bioreactors are passive filtration systems that can reduce nitrate losses from farm fields.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
‘Mini-Brains’ to Study Zika
Novel tool expected to speed research on brain and drug development.
Finding Factors That Protect Against Flu
A clinical trial examining the body’s response to seasonal flu suggests new approaches for evaluating the effectiveness of seasonal flu vaccines.
New Insights into Gene Regulation
Researchers have solved the three-dimensional structure of a gene repression complex that is known to play a role in cancer.
Controlling RNA in Living Cells
Modular, programmable proteins can be used to track or manipulate gene expression.
Common Class of Cancer Drugs May Not Lead to Cognitive Decline
UCLA study refutes 2015 research suggesting anthracyclines could cause memory loss, other impairments.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!